--- title: "SELLAS Life Sciences Group (SLS) stock and investor profile" url: "https://aibio.space/companies/sellas-life-sciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), United States. The directory classifies it as Pharmaceuticals: Major." --- SLS SELLAS Life Sciences Group, Inc. NASDAQ · United States # SELLAS Life Sciences Group (SLS) news Financings · 2025-09-11 ## [SELLAS Life Sciences expects $23.6 million gross from investor's warrant exercise](https://aibio.space/news/sellas-life-sciences-expects-23-6-million-gross-investors-warrant/) SELLAS says an institutional investor will exercise January 2025 warrants for 19,685,040 shares, bringing about $23.6 million gross. The investor gets new unregistered warrants for the same number of shares at $1.88, so the dilution continues. ## Latest SELLAS Life Sciences Group news We have not published a story on SELLAS Life Sciences Group yet. When there is news, it will appear here. ## SELLAS Life Sciences Group at a glance - **Ticker**: SLS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $138.3 million ### Related companies - [Jaguar Health](https://aibio.space/companies/jaguar-health/) NASDAQ: JAGX - [Azitra](https://aibio.space/companies/azitra/) AMEX: AZTR - [Agios Pharmaceuticals](https://aibio.space/companies/agios-pharmaceuticals/) NASDAQ: AGIO - [Syros Pharmaceuticals](https://aibio.space/companies/syros-pharmaceuticals/) OTC: SYRS - [ITonis](https://aibio.space/companies/itonis/) OTC: ITNS - [NOVACCESS GLOBAL INC.](https://aibio.space/companies/novaccess-global/) OTC: XSNX - [Matinas Biopharma Holdings](https://aibio.space/companies/matinas-biopharma/) AMEX: MTNB - [Agentix](https://aibio.space/companies/agentix/) OTC: AGTX ### Also on NASDAQ - [PDS Biotechnology](https://aibio.space/companies/pds-biotechnology/) PDSB - [Lisata Therapeutics](https://aibio.space/companies/lisata-therapeutics/) LSTA - [Anbio Biotechnology](https://aibio.space/companies/anbio-biotechnology/) NNNN - [Liquidia](https://aibio.space/companies/liquidia/) LQDA - [COMPASS Pathways Plc](https://aibio.space/companies/compass-pathways/) CMPS - [Compugen](https://aibio.space/companies/compugen/) CGEN ## SELLAS Life Sciences Group annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [-$26.9 million](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/) | [-$30.9 million](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/) | | Cash from operations | [-$28.4 million](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/) | [-$35.4 million](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/) | | Cash and equivalents | [$71.8 million](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000012/) | [$13.9 million](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $138.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about SELLAS Life Sciences Group What is the ticker symbol of SELLAS Life Sciences Group? SELLAS Life Sciences Group, Inc. trades under the ticker SLS on NASDAQ. Where is SELLAS Life Sciences Group listed? SELLAS Life Sciences Group, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:RXK3; FWB:RXK3; GETTEX:RXK3; HAM:RXK3; HAN:RXK3; LS:A2PU3T; LSX:A2PU3T; MUN:RXK3; SWB:RXK3; TRADEGATE:RXK3; XETR:RXK3. What is the SEC CIK of SELLAS Life Sciences Group? The SEC Central Index Key (CIK) for SELLAS Life Sciences Group, Inc. is 1390478. Its filings are on SEC EDGAR. How many shares does SELLAS Life Sciences Group have outstanding? 201,945,709 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is SELLAS Life Sciences Group listed under? Our directory records SELLAS Life Sciences Group, Inc. under United States. What does SELLAS Life Sciences Group do? Our directory classifies SELLAS Life Sciences Group, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of SELLAS Life Sciences Group? The ISIN recorded for SELLAS Life Sciences Group, Inc. is US81642T2096. Does aibio.space cover SELLAS Life Sciences Group? aibio.space lists SELLAS Life Sciences Group, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is SELLAS Life Sciences Group incorporated? SEC records list its state or country of incorporation as DE. Is SELLAS Life Sciences Group profitable? SELLAS Life Sciences Group, Inc. reported a net loss of $26.9 million for the fiscal year ended Dec 31, 2025, and used $28.4 million of cash in operations, per its annual report to the SEC. How much cash does SELLAS Life Sciences Group have? $138.3 million in cash at Jun 30, 2026, per its 10-Q. What is the latest SELLAS Life Sciences Group (SLS) stock news? Our latest story on SELLAS Life Sciences Group, dated Sep 11, 2025: "SELLAS Life Sciences expects $23.6 million gross from investor's warrant exercise". SELLAS says an institutional investor will exercise January 2025 warrants for 19,685,040 shares, bringing about $23.6 million gross. The investor gets new unregistered warrants for the same number of shares at $1.88, so the dilution continues. [Source](https://aibio.space/news/sellas-life-sciences-expects-23-6-million-gross-investors-warrant/). What is SELLAS Life Sciences Group's latest stock offering or financing news? Our latest financing story, dated Sep 11, 2025: "SELLAS Life Sciences expects $23.6 million gross from investor's warrant exercise". SELLAS says an institutional investor will exercise January 2025 warrants for 19,685,040 shares, bringing about $23.6 million gross. The investor gets new unregistered warrants for the same number of shares at $1.88, so the dilution continues. [Source](https://aibio.space/news/sellas-life-sciences-expects-23-6-million-gross-investors-warrant/). Who were the underwriters or placement agents on SELLAS Life Sciences Group's offering? From our story: The release names A.G.P./Alliance Global Partners and Maxim Group LLC as the financial advisors on the transaction. [Source](https://aibio.space/news/sellas-life-sciences-expects-23-6-million-gross-investors-warrant/). What is SELLAS Life Sciences Group's market cap? We do not publish live share prices. In its annual report, SELLAS Life Sciences Group, Inc. put the market value of shares held by non-affiliates (public float) at $219.1 million as of Jun 30, 2025. ## Investor discussion: SELLAS Life Sciences Group Members talk about SELLAS Life Sciences Group (SLS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at SELLAS Life Sciences Group, newest first. Each line links the filing it comes from. 1. 2025-10-27 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1390478/000110465925102345/tm2529505d1_ex99-1.htm) 2. 2025-09-11 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1390478/000110465925089272/tm2525854d1_ex99-1.htm) 3. 2025-08-12 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000016/sls-20250630.htm) 4. 2025-06-06 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1390478/000110465925057308/tm2517225d1_8k.htm) 5. 2025-01-29 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1390478/000110465925007049/tm254790d1_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SLS on TradingView](https://www.tradingview.com/symbols/NASDAQ-SLS/). ## SEC filings and registration - **SEC name**: SELLAS Life Sciences Group, Inc. - **CIK**: 1390478 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SLS (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 7 TIMES SQUARE, NEW YORK, NY, 10036 - **Phone**: 6462005278 - **Shares outstanding**: 201,945,709 as of 2026-08-10 (10-Q filed 2026-08-11) - **Former names**: GALENA BIOPHARMA, INC.; Galena Biopharma, Inc.; RXI PHARMACEUTICALS CORP ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000013/sls-20260811.htm) filed 2026-08-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000012/sls-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1390478/000110465926087110/tm2621415d1_8k.htm) filed 2026-07-27 - [8-K](https://www.sec.gov/Archives/edgar/data/1390478/000110465926077556/tm2618927d1_8k.htm) filed 2026-06-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1390478/000110465926075775/tm2618311d1_8k.htm) filed 2026-06-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1390478/000110465926069251/tm2616601d1_8k.htm) filed 2026-06-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000009/sls-20260512.htm) filed 2026-05-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000008/sls-20260331.htm) filed 2026-05-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001390478), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details SELLAS Life Sciences Group, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SLS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: SELLAS Life Sciences Group, Inc. - **Ticker**: SLS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US81642T2096 - **Other listed symbols**: DUS:RXK3; FWB:RXK3; GETTEX:RXK3; HAM:RXK3; HAN:RXK3; LS:A2PU3T; LSX:A2PU3T; MUN:RXK3; SWB:RXK3; TRADEGATE:RXK3; XETR:RXK3 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SLS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/sellas-life-sciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "SELLAS Life Sciences Group (SLS) stock and investor profile", 2026-10-31, https://aibio.space/companies/sellas-life-sciences/